Ultrasensitive assays for alpha synuclein biomarkers in neurodegeneration research

This resource highlights ultrasensitive assays for measuring total α‑synuclein and phosphorylated α‑synuclein (pS129) as key biomarkers in Parkinson’s disease and related synucleinopathies. Using the SPEAR UltraDetect™ α‑syn and pS129‑α‑syn assays, researchers can achieve femtogram‑level detection in plasma, serum, and cerebrospinal fluid, enabling precise quantification and longitudinal monitoring of disease‑associated changes. The assays support improved biomarker discovery and therapeutic research by enabling sensitive detection of low‑abundance targets and analysis of biomarker ratios for disease differentiation.